Mitoglitazone: Phase IIb started

Last month, Metabolic Solutions began a double-blind, placebo-controlled, U.S. and Indian Phase IIb trial in about 420 Type II diabetics to compare once-daily 50, 100 and 150 mg mitoglitazone vs. once...